translation agency

NLM AIDSLINE
Survival among injecting drug users with AIDS, United States, 1988-1990.
Neal JJ; Fleming PL; Green TA; Chu SY; Burgess DA; Centers for Disease
December 30, 1994
Int Conf AIDS. 1994 Aug 7-12;10(1):300 (abstract no. PC0126). Unique

OBJECTIVE: Most estimates of survival time after AIDS diagnosis have been based on studies of white men who have sex with men (MSM). We examined survival time after AIDS diagnosis among heterosexual injecting drug users (IDUs). METHODS: Reports of persons > or = 15 years of age with AIDS diagnosed from 1988 through 1990 and reported to CDC through June 1993 were selected from the 14 states and 3 cities that cross-match AIDS reports with the National Death Index. We used the product-limit method to calculate median survival time in months after AIDS diagnosis and survival time by year of diagnosis for MSM and IDUs. For IDUs, we also calculated survival time by sex, race/ethnicity, and geographic region of residence. Observations were censored in June 1992 to minimize bias caused by reporting delays. Differences in survival time were tested for significance at the p < .01 level. RESULTS: The median survival time was shorter for IDUs (14 months, n = 14,760) than for MSM (19 months, n = 34.425). Survival time increased by diagnosis year from 1988 through 1992 among both IDUs (13 months to 16 months) and MSM (18.5 months to 20 months). Among IDUs, survival time was shorter for older persons (11 months for persons aged 45-64) than for younger persons (19 months for persons aged 15-24), for blacks and Hispanics (both 13 months) than for whites (19 months), and for persons living in the Northeast (13 months) than in other regions (19 months). No significant differences in survival time by sex were found. DISCUSSION AND CONCLUSIONS: Differences in survival time by risk, diagnosis year, age, race, and region may be attributable to the effects of injected drugs or to differences in access to and use of HIV-related and other health-care services.

Acquired Immunodeficiency Syndrome/*MORTALITY/TRANSMISSION Adolescence Adult Female Human Male Middle Age Substance Abuse, Intravenous/*COMPLICATIONS United States/EPIDEMIOLOGY ABSTRACT

www.aegis.org